Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons. (PubMed, Acta Derm Venereol) - Apr 18, 2026 - "This study evaluated the comparative effectiveness of Xeligekimab vs Secukinumab and Ixekizumab through matchingadjusted indirect comparisons (MAICs). At week 60, Xeligekimab maintained significantly higher PASI 75 vs Ixekizumab (92.6% vs 76.1%, p<0.001) with lower infection rates during induction period (7.9% vs 34.7%, p<0.001) and maintenance period (22.4% vs 56.5%, p<0.001). This MAIC provides hypothesis-enerating evidence that Xeligekimab may offer advantages in specific long-term efficacy endpoints and safety outcomes, requiring confirmation in direct randomized controlled trials."
Clinical • Journal • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A
|